|Bid||16.84 x 0|
|Ask||16.86 x 0|
|Day's range||16.74 - 17.19|
|52-week range||15.08 - 26.07|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||17.35|
|Earnings date||24 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||0.36 (2.22%)|
|Ex-dividend date||03 Jun 2021|
|1y target est||25.40|
MADRID (Reuters) -Spanish pharmaceuticals company Grifols proposed a 1.6 billion euro ($1.9 billion) takeover of its German rival Biotest on Friday, in a move to consolidate the plasma-based drug industry. Grifols said it had agreed with Tiancheng International Investment to buy the Hong Kong-based company's controlling stake in Biotest for 1.1 billion euros. The Barcelona-based company agreed to buy 89.88% of Biotest's ordinary shares that carry voting rights, but which represent only 44.54% of the company's capital, and a further 0.54% of capital in preferred shares that do not carry voting rights, from Hong Kong-based Tiancheng.
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today